In Focus channel feed – Endpoints News

In Focus channel feed

Inversago was working toward a potential 2024 IPO, but Novo’s interest won out. CB1 biotechs hope to ride the wave

Last year

His tiny prenatal testing company has big plans after exacting legal revenge on lab giants

Last year

As Vertex’s pivotal pain readout looms, non-opioid drug development faces a reckoning

Last year

‘This is not a science problem anymore': Paths emerge for scaling up rare disease medicine

Last year

‘The sleeping giant is waking up’: FTC raises the pressure on pharma dealmaking

Last year

'Moderna will be a rare disease company,' CEO says, as mRNA company plots expansion in genetic diseases and eyes n-of-1 treatments

Last year

Escaping an improbable upbringing, Greg Verdine places his biggest career bets in drugging the ‘undruggable’

Last year

Rich Horgan spearheaded a gene therapy for his brother. The trial ended in tragedy, but the work continues for more patients

Last year

Families raised millions and handed rare disease therapies off to biotechs. But companies have backed out

Last year

CAR-T reshaped cancer treatment. Can it change autoimmune disease, too?

3 years ago

No longer ‘dead or just hibernating,’ drugmakers return to heart medicines

3 years ago

Rare disease trials can't find enough patients. It's forcing the FDA to rethink its approach

3 years ago

‘Harder to find homes’: Latest wave of biotech layoffs could test the industry

3 years ago

A radioactive prostate cancer therapy is a last lifeline for patients. Novartis can't make enough of it

3 years ago

Decades after breakthrough, scientists still puzzling over mRNA delivery

3 years ago

Thousands of gene and cell therapies are inundating FDA reviewers as the agency tries to keep up

3 years ago

How Purdue's $272M addiction payout funded a new home for its discarded non-opioid research

3 years ago

A stem cell pioneer sent an experiment into space. Patients are the next frontier

3 years ago

The conference is back. What about the industry? Taking the biotech pulse at #JPM23

3 years ago

As money pours into digital therapeutics, insurance coverage crawls

3 years ago

Covid-19 spurred a historic vaccine R&D effort. What does it mean for future pandemics?

3 years ago

A biotech paused a gene therapy hatched by families. Now they want control

3 years ago

Father starts lab after intellectual property issues stymie rare disease drug development

3 years ago

Even as pandemic recedes, short-staffed trial sites leave cancer patients waiting

3 years ago

First page Previous page 1 2 345 6 7 Next page Last page